A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Terminated
Study type
Observational
Enrollment
43actual
Sites
4
Countries
Brazil, Israel, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Due to recruitment challenges, the sponsor has decided to terminate the study prematurely.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-29 | actual | When the study began enrolling |
| Primary completion | 2025-03-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-21 | actual | The whole study's end, after follow-up |
| First posted | 2023-06-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Idiopathic Short Stature
Intervention
- Other: No treatment is given
Primary outcome
what the primary-completion date above is the date OFThe frequency of genetic variants that significantly differ between the two responder groups
measured One year after growth hormone therapy
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed